What is being done to prevent additional fatal infections?
Danco Laboratories, the manufacturer of Mifeprex, includes extensive warnings in the information given to patients and health care professionals. With approval from the FDA, Danco issued a letter alerting providers of medical abortion and emergency room health care providers to the occurrence of C. sordellii infection with presentation of atypical symptoms, such as the lack of fever. It is unknown whether antibiotics would prevent the fatalities from C. sordellii. Preventive antibiotic use carries its own set of risks, including severe or fatal allergic reactions and growth of drug-resistant strains of bacteria.5 Because the reports of severe infection following medical abortion are rare and management with antibiotics is not well-established, the FDA continues to recommend against prophylactic antibiotics following use of mifepristone.
